Chemistry:7-Hydroxycannabidiol
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| Chemical and physical data | |
| Formula | C21H30O3 |
| Molar mass | 330.468 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
7-Hydroxycannabidiol (7-OH-CBD) is an active metabolite of cannabidiol, generated in the body from cannabidiol by the action of the enzyme CYP2C19.[1] While methods have been developed for its synthetic production,[2] and measurement of levels in the body following consumption of cannabidiol,[3] its pharmacology has been relatively little studied, though it has been found to possess similar anticonvulsant effects to cannabidiol itself,[4] as well as lowering blood triglyceride levels. Like its precursor CBD, it is not known to exhibit any psychoactive effects on the body and is known to counter the psychoactive effects of THC if it is present at the same time. This mode of action in 2015 was discovered to be at least contributing in part by being a non competitive negative allosteric modulator of the Cannabinoid receptor type 1.[5]
See also
- 4'-Fluorocannabidiol
- 8,9-Dihydrocannabidiol
- 8,11-Dihydroxytetrahydrocannabinol
- 11-Hydroxy-THC
- Cannabidiolic acid
- Cannabidiol dimethyl ether
- Delta-6-Cannabidiol
- HU-308
- HU-320
- KLS-13019
References
- ↑ "Cannabidiol - therapeutic and legal aspects". Die Pharmazie 75 (10): 463–469. October 2020. doi:10.1691/ph.2020.0076. PMID 33305718.
- ↑ "Synthesis of a primary metabolite of cannabidiol". Organic Letters 2 (21): 3301–3. October 2000. doi:10.1021/ol006369a. PMID 11029195.
- ↑ "Disposition of Cannabidiol Metabolites in Serum and Urine from Healthy Individuals Treated with Pharmaceutical Preparations of Medical Cannabis". Pharmaceuticals (Basel, Switzerland) 13 (12): 459. December 2020. doi:10.3390/ph13120459. PMID 33322849.
- ↑ Colin S, Nick Jones N, Whalley B, Stephens G, Williams C, "7-hydroxy-cannabidiol (7-OH-CBD) and/or 7-oh-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy.", WO patent 2015198078, published 30 December 2015, assigned to GW Pharma Limited
- ↑ Stott C, Duncan M, Di Marzo V, Silverstri C, Martella A, "7-Hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)", WO patent 2015198077, published 30 December 2015, assigned to GW Pharma Limited
 |  |
